JP2008514577A - Ｚｄ６４７４及びイマチニブを含んでなる組合せ - Google Patents

Ｚｄ６４７４及びイマチニブを含んでなる組合せ Download PDF

Info

Publication number
JP2008514577A
JP2008514577A JP2007532963A JP2007532963A JP2008514577A JP 2008514577 A JP2008514577 A JP 2008514577A JP 2007532963 A JP2007532963 A JP 2007532963A JP 2007532963 A JP2007532963 A JP 2007532963A JP 2008514577 A JP2008514577 A JP 2008514577A
Authority
JP
Japan
Prior art keywords
imatinib
pharmaceutically acceptable
warm
effective amount
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008514577A5 (US07981874-20110719-C00313.png
Inventor
ウェッジ，スティーブン・ロバート
Original Assignee
アストラゼネカ アクチボラグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0421438A external-priority patent/GB0421438D0/en
Priority claimed from GB0506726A external-priority patent/GB0506726D0/en
Application filed by アストラゼネカ アクチボラグ filed Critical アストラゼネカ アクチボラグ
Publication of JP2008514577A publication Critical patent/JP2008514577A/ja
Publication of JP2008514577A5 publication Critical patent/JP2008514577A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007532963A 2004-09-27 2005-09-23 Ｚｄ６４７４及びイマチニブを含んでなる組合せ Pending JP2008514577A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0421438A GB0421438D0 (en) 2004-09-27 2004-09-27 Combination therapy
GB0506726A GB0506726D0 (en) 2005-04-01 2005-04-01 Combination therapy
PCT/GB2005/003673 WO2006035204A2 (en) 2004-09-27 2005-09-23 Combination comprising zd6474 and an imatinib

Publications (2)

Publication Number Publication Date
JP2008514577A true JP2008514577A (ja) 2008-05-08
JP2008514577A5 JP2008514577A5 (US07981874-20110719-C00313.png) 2008-08-28

Family

ID=35924044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532963A Pending JP2008514577A (ja) 2004-09-27 2005-09-23 Ｚｄ６４７４及びイマチニブを含んでなる組合せ

Country Status (11)

Country Link
US (2) US20080119479A1 (US07981874-20110719-C00313.png)
EP (1) EP1804802A2 (US07981874-20110719-C00313.png)
JP (1) JP2008514577A (US07981874-20110719-C00313.png)
KR (1) KR20070072543A (US07981874-20110719-C00313.png)
AU (1) AU2005288737B2 (US07981874-20110719-C00313.png)
BR (1) BRPI0516052A (US07981874-20110719-C00313.png)
CA (1) CA2578956A1 (US07981874-20110719-C00313.png)
IL (1) IL181609A0 (US07981874-20110719-C00313.png)
MX (1) MX2007003505A (US07981874-20110719-C00313.png)
NO (1) NO20071428L (US07981874-20110719-C00313.png)
WO (1) WO2006035204A2 (US07981874-20110719-C00313.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520226A (ja) * 2012-06-18 2015-07-16 アジョウ・ユニバーシティ・インダストリー−アカデミック・コーポレイション・ファウンデイションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ イマチニブまたはこの薬学的に許容される塩を有効成分として含む血管透過性疾患の治療若しくは予防用組成物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
EP1592423B1 (en) * 2003-02-13 2011-04-20 AstraZeneca AB Combination therapy of zd6474 with 5-fu and/or cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
DE602004028834D1 (de) * 2003-07-10 2010-10-07 Astrazeneca Ab Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
WO2009111472A2 (en) 2008-03-03 2009-09-11 Nike, Inc. Interactive athletic equipment system
US8231506B2 (en) 2008-12-05 2012-07-31 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
US8628453B2 (en) 2008-12-05 2014-01-14 Nike, Inc. Athletic performance monitoring systems and methods in a team sports environment
US20100184564A1 (en) 2008-12-05 2010-07-22 Nike, Inc. Athletic Performance Monitoring Systems and Methods in a Team Sports Environment
KR101560955B1 (ko) 2010-11-10 2015-10-15 나이키 이노베이트 씨.브이. 시간 기반 체육 활동 측정 및 표시를 위한 시스템 및 방법
CN103748589B (zh) 2011-02-17 2017-12-12 耐克创新有限合伙公司 跟踪用户锻炼期间的表现指标
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
KR101778004B1 (ko) 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
SG11202001720RA (en) 2017-07-26 2020-03-30 Ftf Pharma Private Ltd Liquid dosage forms of imatinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
WO2003090686A2 (en) * 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
JP2006502132A (ja) * 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
EP1592423B1 (en) * 2003-02-13 2011-04-20 AstraZeneca AB Combination therapy of zd6474 with 5-fu and/or cpt-11
DE602004028834D1 (de) * 2003-07-10 2010-10-07 Astrazeneca Ab Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
EP1796672A1 (en) * 2004-09-27 2007-06-20 AstraZeneca AB Cancer combination therapy comprising azd2171 and imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
SI1971338T1 (sl) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija ZD6474 in pemetrekseda

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032651A1 (en) * 1999-11-05 2001-05-10 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
WO2003090686A2 (en) * 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520226A (ja) * 2012-06-18 2015-07-16 アジョウ・ユニバーシティ・インダストリー−アカデミック・コーポレイション・ファウンデイションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ イマチニブまたはこの薬学的に許容される塩を有効成分として含む血管透過性疾患の治療若しくは予防用組成物

Also Published As

Publication number Publication date
NO20071428L (no) 2007-04-02
US20080119479A1 (en) 2008-05-22
EP1804802A2 (en) 2007-07-11
BRPI0516052A (pt) 2008-08-19
WO2006035204A2 (en) 2006-04-06
AU2005288737A1 (en) 2006-04-06
AU2005288737B2 (en) 2008-08-14
KR20070072543A (ko) 2007-07-04
US20100069398A1 (en) 2010-03-18
WO2006035204A3 (en) 2006-10-19
IL181609A0 (en) 2007-07-04
MX2007003505A (es) 2007-05-10
CA2578956A1 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
JP2008514577A (ja) Ｚｄ６４７４及びイマチニブを含んでなる組合せ
AU2005288736B2 (en) Cancer combination therapy comprising AZD2171 and imatinib
CA2531862C (en) Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AU2006328189A1 (en) Combination of ZD6474 and pemetrexed
JP2010504949A (ja) Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
CA2631676A1 (en) Combination of azd2171 and pemetrexed
EP1729808B1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
JP2007530517A (ja) 組合せ療法
US20090176731A1 (en) Combination therapy of cancer with azd2171 and gemcitabine
WO2005092385A2 (en) Combination therapy of azd2171 and a taxane
WO2009118560A1 (en) Combination therapy 038
ZA200600186B (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of deseases associated with angiogenesis and/or increased vascular permeability

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080711

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120823